Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. develops and commercializes fertility-control products for managing animal pest populations, with current products focused on rat and mouse populations. Its product names include ContraPest, Evolve Rat, and Evolve Mouse, which are used within pest-management programs as alternatives or complements to traditional rodent-control methods.
Company news centers on Evolve commercialization, e-commerce and direct-to-consumer sales channels, Amazon marketplace management, field-study data on rodent activity, product approvals in international markets, quarterly and annual financial results, capital runway commentary, and executive leadership or board governance updates.
SenesTech, Inc. (NASDAQ: SNES) reported a 138% increase in Q1 2021 revenues to approximately $88,000 year-on-year, with operating expenses reduced by 20%. The company, specializing in rodent fertility control, experienced significant traction in California due to legislation prohibiting certain rodenticides. Cash reserves stand at $15.2 million, supporting future growth. Notable successes included significant population reductions of rats observed in agricultural settings. The firm has transitioned to a solutions-based model and rebranded itself as 'The Pest Control Difference.'
SenesTech, Inc. (NASDAQ: SNES), known for its innovative fertility control solutions for pest management, will release its financial results for the first quarter of 2021 on May 13, 2021, after market close. A conference call to discuss the results is scheduled for the same day at 5:00 pm ET. The company emphasizes its commitment to revolutionizing pest control through its proprietary technology, ContraPest®, which targets reproduction in rat populations. This approach aims to reduce reliance on lethal pest management methods.
SenesTech (NASDAQ: SNES) has launched a new brand campaign, "The Pest Control Difference," highlighting its revolutionary ContraPest® product aimed at managing rodent populations through fertility control. The rebrand signifies the company's transition to a solutions-oriented, environmentally responsible entity within pest management. ContraPest®, proven effective in reducing rat populations non-lethally, is now available for use across all 50 states. Key initiatives include partnerships with distributors and a new loyalty program.
SenesTech, Inc. (NASDAQ: SNES) has renewed and expanded its distribution agreement with Agri-Turf Distributing for ContraPest in California. This partnership aims to enhance the marketing and sales of ContraPest, which effectively controls rat populations through fertility management. With Agri-Turf's expertise in pest management, both companies plan joint marketing initiatives to meet growing demand. ContraPest targets reproductive capabilities in rats, providing a safe, non-lethal pest control solution. The collaboration marks an important step in SenesTech's strategy to revolutionize pest management.
SenesTech, Inc. (NASDAQ: SNES) reported a 97% increase in revenue for 2020, totaling approximately $282,000, compared to $143,000 in 2019. Key deployments of ContraPest demonstrated significant success in reducing rat populations by 90% at an egg production farm and 99% at an urban site. The California Ecosystems Protection Act now prohibits certain rodenticides, offering a potential $100 million market for ContraPest. Despite a net loss of $(8.4) million, improved operational efficiency and successful fundraising efforts position SenesTech well for future growth.
SenesTech, Inc. (NASDAQ: SNES) has partnered with Liphatech, Inc. to develop a non-liquid formulation of ContraPest®, an innovative pest management product aimed at controlling rat populations through fertility control. This collaboration aims to leverage Liphatech's expertise in soft bait technology and SenesTech's proven formula to create a new product offering. ContraPest has successfully reduced rat populations over five years of deployment, currently available in a liquid form approved by the EPA. The development of a new formulation represents a strategic expansion of SenesTech's pest control solutions.
SenesTech, Inc. (NASDAQ: SNES), a leader in fertility control technologies for pest management, announced its participation at the Lytham Partners Spring 2021 Investor Conference on March 31, 2021, at 12:30 PM ET. A webcast of the presentation will be available on the company's website and archived for later access. The event runs from March 30 to April 1, 2021, with virtual one-on-one meetings available by arrangement. SenesTech aims to revolutionize pest control with its product, ContraPest®, which targets reproduction in rat populations, promoting a non-lethal approach.
SenesTech, Inc. (NASDAQ: SNES) has completed a registered direct offering of 1,975,000 shares of common stock priced at $2.00 each, generating gross proceeds of $3.95 million. The funds will be allocated for working capital and general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for this offering. The shares were made available under a previously effective shelf registration statement filed with the SEC.
SenesTech, Inc. (NASDAQ: SNES) announced successful results from a long-term study of its fertility control product, ContraPest®, in an east coast urban area. The study demonstrated a 94% reduction in rat activity at Site A and a 99% reduction at Site B, with juvenile rat populations declining by 98% and 100%, respectively. The city's integrated pest management program plans to expand the deployment of ContraPest® as part of a comprehensive rodent control strategy. CEO Ken Siegel emphasized the potential for similar applications in urban settings across the U.S.
On March 19, 2021, SenesTech (NASDAQ: SNES) announced a registered direct offering of 1,975,000 shares of common stock at $2.00 per share, aiming for gross proceeds of $3.95 million. The offering is set to close around March 23, 2021, subject to customary conditions. Proceeds will be utilized for working capital and corporate purposes. H.C. Wainwright & Co. is the placement agent for this offering, which follows a Form S-3 registration statement effective since August 24, 2018.